Deutsche Bank raised the firm’s price target on Hims & Hers to $28 from $25 and keeps a Hold rating on the shares. The company announced a new partnership with Novo Nordisk and a strategic shift in its GLP-1 offerings away from compounded semaglutide, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Citi upgrades Hims & Hers to Neutral on Novo pact renewal
- Hims & Hers upgraded to Neutral from Sell at Citi
- Needham Upgrades Hims & Hers Stock (HIMS) after Novo Nordisk Deal Resets Weight Loss Outlook
- Morning News Wrap-Up 3/9/26: Monday’s Biggest Stock Market Stories!
- Moderately bullish activity in Hims and Hers Health with shares up 39.33%